Clinical Trials Logo

Clinical Trial Summary

Sunitinib may provide an opportunity for a novel therapeutic strategy for the treatment of subjects with neuroendocrine tumors.


Clinical Trial Description

With the exception of surgery for localized disease, there is presently a lack of available therapies with proven survival benefit for patients with neuroendocrine tumors (NET). Available treatment options for unresectable disease include the use of somatostatin analogs, which may relieve symptoms related to hormonal hypersecretion. The efficacy of cytotoxic chemotherapy in patients with metastatic carcinoid tumors is also limited. Combinations of either streptozocin and cyclophosphamide, or streptozocin and 5-fluorouracil, appear to be inactive, and both regimens are associated with substantial toxicity.

Receptor tyrosine kinases (RTKs) are implicated in deregulated/ autocrine proliferation and survival of solid and hematologic cancer cells. Sunitinib malate is an orally administered small molecule that inhibits the tyrosine kinase enzymatic activities of the receptors for VEGF and PDGF, and also blocks signalling through the KIT, FLT3 and RET pathways.

Therefore, sunitinib malate may provide an opportunity for a novel therapeutic strategy for the treatment of subjects with NET. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01731925
Study type Interventional
Source Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Contact
Status Active, not recruiting
Phase Phase 2
Start date January 7, 2013
Completion date December 2017

See also
  Status Clinical Trial Phase
Completed NCT02441062 - Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors Phase 2
Completed NCT00580320 - Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma Phase 1
Completed NCT02575300 - Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Phase 2
Active, not recruiting NCT02441088 - Theranostics: 68GaDOTATOC and 90YDOTATOC Phase 2
Terminated NCT00227136 - Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion Phase 3
Terminated NCT00947167 - A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors Phase 2
Terminated NCT02177773 - GA-68 DOTA-TOC of Somatostatin Positive Malignancies Phase 1/Phase 2
Active, not recruiting NCT02795858 - A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors Phase 2
Terminated NCT02859064 - Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres Phase 2
Completed NCT00088595 - Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors Phase 2
Completed NCT01619865 - Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors Phase 1/Phase 2
Completed NCT01253161 - Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) Phase 2
Terminated NCT02359500 - 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs) Phase 1
No longer available NCT01980732 - 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors N/A
Not yet recruiting NCT01373736 - 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Phase 3